
EUDAMED’s first four modules become mandatory on 28 May 2026 - what this means for medical device manufacturers
The European Commission (EC) has formally declared that the first four modules of EUDAMED - the European Database on Medical Devices - will become mandatory as of 28 May 2026.
Which modules are affected
Starting on 28 May 2026, the following modules will require compulsory use under Regulation (EU) 2024/1860:
- Actor registration (registration of economic operators - manufacturers, authorised representatives, importers, etc.)
- UDI/Devices registration (device registration and unique device identifier requirements)
- Notified Bodies & Certificates (registration of notified bodies and associated device certificates)
- Market Surveillance (module supporting oversight of devices on the market)
Timing and transition
The EC published the notice declaring functionality of these modules on 27 November 2025, triggering the mandated six-month transition period under the Regulation - hence the effective date of 28 May 2026.
Until that date, use of the modules remains voluntary, but after 28 May 2026 their use becomes a legal requirement for any responsible economic operator under MDR/IVDR.
Conclusions & Recommendations
- The mandatory activation of the first four EUDAMED modules from 28 May 2026 signals a major shift toward increased transparency and regulatory compliance across the EU medical device market.
- All manufacturers, authorised representatives, importers, and notified bodies should review their readiness - including internal processes and data - to ensure timely registration.
- With our expertise, MedNet EC-REP GmbH can help navigate the transition smoothly. Contact your Regulatory Affairs Manager for further information.
Source: European Commission
Latest news

MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its “DORS Fees Guidance 2.1”, introducing a new annual fee model for device registration.

MedNet EC-REP GmbH to Exhibit at WHX 2026 in Dubai
MedNet EC-REP GmbH is excited to announce its participation in WHX 2026, taking place from February 9–12 in Dubai. As a trusted European Authorized Representative and compliance partner for global medical device manufacturers, we look forward to presenting our comprehensive regulatory services to an international audience.

Implications of the Update to the Borderline & Classification Manual under MDR and IVDR
On 12 September 2025, the European Commission published Version 4 of the Manual on Borderline and Classification under Regulations (EU) 2017/745 and 2017/746, developed by the Borderline and Classification Working Group (BCWG).

Regulatory Affairs Bulletin: Intended Purpose vs Intended Use under MDR & IVDR
European regulations EU 2017/745 (MDR) and EU 2017/746 (IVDR) require precise definitions in technical documentation, and the distinction (or overlap) between intended purpose and intended use remains a topic of operational significance.
-250x250.jpg&w=256&q=75)
MedNet EC-REP GmbH at MEDICA 2025 – Visit Us in Hall 3, Booth D43
MedNet EC-REP GmbH is pleased to announce that we will once again be exhibiting at MEDICA 2025 in Düsseldorf, the world’s leading trade fair for the medical technology industry.

EU eIFU Regulation Update Draft: What Medical Device Professionals Need to Know
The European Commission has introduced a significant amendment to Implementing Regulation (EU) 2021/2226, impacting how medical device manufacturers provide instructions for use (IFU).

Understanding the Interplay: MDR, IVDR, and the AI Act – Key Insights from MDCG 2025-6
Recently, the MDCG, in conjunction with the Joint Artificial Intelligence Board (AIB), released the MDCG 2025-6 FAQ document, offering essential clarifications on the interplay between the MDR, the IVDR, and the Artificial Intelligence Act (AIA).